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A convenient synthesis of novel isoxazole-substituted 9-anilinoacridine derivatives 5a–j was reported. The compounds were
conﬁrmed by physical and analytical data and screened for in vitro antioxidant activity by DPPH method, reducing power assay
and total antioxidant capacity method. The cytotoxic activity of the compounds was also studied in HEp-2 cell line. The docking
studiesofthesynthesizedcompoundswereperformedtowardsthekeynucleosidedsDNAbyusingAutoDockvina4.0programme.
All the isoxazole-substituted compounds have signiﬁcant activities.
1.Introduction
Acridine derivatives are used in medicine and have enor-
mous potential as pharmaceutical agents due to their
biological activities such as antimicrobial [1], antioxidant
[2], anticancer [3–5], antimalarial [6], anti-inﬂammatory
[7], analgesic [8], antileishmanial [9], and so forth. The
chemical modiﬁcation of acridines such as the introduction
of diﬀerent substitutions or heterocyclic rings were allowed
expansion of research on the structure activity relationship
to aﬀord new insight into molecular interactions at the
receptor level [10]. In fact, it is well established that slight
structural modiﬁcation on 9-anilinoacridines may bring
various pharmacological eﬀects. Similarly isoxazoles [11–
13] also have various biological activities like as antimicro-
bial, anticancer, and so forth. In order to look for some
new compounds with interesting biological properties, we
would like to synthesize some novel isoxazole-substituted 9-
anilinoacridine derivatives.
2. Experimental
All the organic solvents used were of high purity unless
otherwise stated. The reactions were monitored by TLC
on silica gel thin layer plates. Elemental analysis (C, H,
N; Elementar Vario EL III Instrument), melting points (in
glass capillary tubes on a Veego VMP-1 Apparatus), IR
spectra (Shimadzu 8400 FT-IR spectrometer), 1HN M Ra n d
13C NMR (Bruker A VIII 500MHz Spectrometer) spectra
have been recorded. Mass spectra of the ﬁnal compounds
were recorded on a JEOL GC mate Mass Spectrometer. The
synthetic procedure was explained in the Scheme 1.
2.1. Synthesis of 1-[4-(Acridin-9-Ylamino)Phenyl]Ethanone 3.
In a 250mL round-bottomed ﬂask 4.06g (0.03 mole) of
4-aminoacetophenone was reﬂuxed with 5.4528g (0.0256
mole) of 9-chloroacridine in 80mL of 2-butanol for 3h.
After completion of reaction the reaction mixture was al-
lowed to cool to room temperature then it was poured into
150mL of ice water. A precipitate formed was ﬁltered by
suction, washed with water, dried, and recrystallized from
ethanol.
2.2. General Procedure for Synthesis of Chalcones 4a–j. The
chalconesweresynthesizedbyusinggeneralClaisen-Schimdt
condensation. In a 100mL ﬂat-bottomed ﬂask 25mL of the
10% sodium hydroxide and 25mL of ethanol were taken
with a magnetic stirring bar, it was placed on the magnetic
stirrer, and the stirring dial was adjusted to get a nice,
even stirring action. To this 0.0115 mole of corresponding2 The Scientiﬁc World Journal
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aldehyde was added, then 2.9952g (0.0096 mole) of 1-[4-
(acridin-9-ylamino)phenyl]ethanone was added at the last.
The solution was allowed to stir for 8h at room temperature.
After completion of the reaction 100mL of water was added,
formed precipitate was ﬁltered and washed three times with
50mL of water each time to remove sodium hydroxide,
dried, and crystallized from ethanol. All the compounds
are characterized and conﬁrmed by IR, NMR, and mass
spectroscopy. All the values are agreed with the synthesized
compounds.
Theyield ofcompounds is between60and 85%;IR (KBr,
ν,c m −1)f o rc o m p o u n d4a: 3269 (N–H), 3057-3000 (Ar C–
H), 1647 (α,β-unsat. C=O), 1604 & 1516 (Ar C=C), 1226
(C–N), 759 (Ar C–H); ms:m/z 400.16 (M+); 1H NMR (in
ppm): 6.65–8.02 (16H, m, ArH), 7.90 and 7.56 (2H, s, α,β-
unsaturated), 11.21 (1H, s, NH); 13C NMR (in ppm): 183.4,
153.8, 149.8, 142.8, 140.5, 136.1, 135.4, 131.7, 131.3, 130.4,
129.3, 129.8, 128.9, 127.8, 126.7, 126.7, 121.9, 119.3, 115.7.
2.3. General Procedure for Synthesis of Isoxazole-Substituted
9-Anilinoacridines 5a–j. Ina25mLbeaker ,2.5g(0.02mol)
anhydrous sodium acetate was dissolved in minimum
amount of hot glacial acetic acid (10mL) and it was added to
a solution of 0.81g (0.01mol) hydroxyl amine hydrochloride
in absolute ethanol (10mL). A solution of 0.01mol of the
corresponding chalcones 4a–j in 10mL of absolute ethanol
and the above solution were reﬂuxed for 6 hours in oil
bath. The reaction was monitored by TLC (pet ether: ethyl
acetate 3:2). After completion of the reaction excess solvent
was concentrated in vacuo at reduced pressure, residual
solution obtained was cooled to room temperature, poured
into ice cold water, neutralized with sodium hydroxide, and
washed well with water to remove unreacted hydroxyl amine
hydrochloride and excess of sodium hydroxide. Dried crude
product yield was noted and recrystallized from ethanol. All
thecompoundsarecharacterizedandconﬁrmedbyIR,NMR
and mass spectroscopy. All the values are agreed with the
synthesized compounds.
This compound is obtained as a yellow powder; m.p.:
170–172◦C; Yield: 56%; Anal. calc. for C28H19N3O: C, 81.34;
H, 4.63; N, 10.16; O, 3.87. Found: C, 81.21; H, 4.42; N, 10.1;
IR (KBr, ν,c m −1): 3340 (N–H), 2993 (Ar st C–H), 1600 &
1473 (Ar C=C), 1157 (Ar C=N), 1226 (C–O), 742 (Ar C–H);
MS: m/z 413.15 (M+); 1H NMR (in ppm): 6.85–8.94 (16H,
m, ArH), 9.95 (1H, s, CH of isoxazole), 11.10 (1H, s, 9-NH);
13C NMR (in ppm): 98.4 (C of isoxazole), 114.8–143.1 (27
aromatic carbons).
2.4. Molecular Docking. The computer-simulated automated
docking studies were performed using the widely distributed
molecular docking software, AutoDock Vina 4.0. The pro-
teins were extracted from protein database at the NCBI,
that is, dsDNA octamer duplex (1XRW). The designed 9-
anilinoacridine analogues were taken for prediction of 3DThe Scientiﬁc World Journal 3
structure by using Cambridge software. The energy was
minimized for ﬂexible docking using Argus Lab, for the
docking of ligands to protein active sites and for estimating
the binding aﬃnities of docked compounds by an advanced
molecular docking program AutoDock Vina, version 4.0.
Predicting the binding aﬃnity and rank-ordering ligands
in database screens was implemented by modiﬁed and
expanded version of the ChemScore18 scoring functions, for
use.Usingstandardprecision(SP)modeofPyMOLsoftware,
docking studies were performed on planned compounds for
synthesis. The structures of the compound and enzymes are
shown in Figure 1.
3.Biological Evaluation
Acridine derivatives possess a diverse range of pharma-
cological activities [14–16]. Hence all the chalcone and
isoxazole-substituted 9-anilino acridine derivatives 4a–j,5a–
j were screened for antioxidant activity and short-term in
vitro antitumor activity against Daltons Lymphoma Ascites
(DLAs) cells. Many of the synthesized ﬁnal compounds 5a–j
have signiﬁcant activities.
3.1. Antioxidant Activity
3.1.1. DPPH Assay [17]. The assay was carried out in
a 96-well microtitre plate. To 200μL of DPPH solution,
10μL of each of the synthesized or standard solution was
added separately in wells of the microtitre plate. The ﬁnal
concentration of the synthesized compounds and standard
solutions used were 1000, 500, 250, 125, 62.5, 31.25, and
15.625, 7.812μg/mL. The plates were incubated at 37◦Cf o r
30min and the absorbance of each solution was measured at
490nm, using ELISA reader. The percentage inhibition was
calculated. IC50, which is the concentration of the sample
required to scavenge 50% of free radicals.
3.1.2. Reducing Power Assay [18]. 10mL of each of the
synthesized or standard solution was added separately in
1.0mL of deionized water that were mixed with phosphate
buﬀer (2.5mL) and potassium ferri cyanide (2.5mL). The
mixture was incubated at 50◦C for 20min. Aliquots of
trichloroacetic acid (2.5mL) were added to the mixture,
whichwasthencentrifugedat3000rpmfor10minwhenever
necessary. The upper layer of solution (2.5mL) was mixed
with distilled water (2.5mL) and a freshly prepared ferric
chloride solution (0.5mL). The absorbance was measured
at 700nm. Ascorbic acid at various concentrations was used
as a reference standard. Phosphate buﬀer (pH 6.6) was
used as blank solution. The absorbance of the compounds
takenwasexpressedasmean ±standarddeviation.Increased
absorbance of the reaction mixture indicates increase in
reducing power.
3.1.3. Antioxidant Potential Assay by Phosphomolybdenum
Method [19]. The antioxidant power of the compounds
has been assessed with the phosphomolybdenum reduction
assay according to Armatu et al. The assay is based on the
reduction of Mo(VI)-Mo(V) by the compounds and subse-
quent formation of a green phosphate—Mo(V) complex at
acid pH. Various concentrations compounds were combined
with 3mL of reagent solution (0.6M sulfuric acid, 28mM
sodium phosphate, and 4mM ammonium molybdate). The
tubes containing the reaction solution were incubated at
95◦C for 90min. Then the absorbance of the solution was
measured at 695nm using spectrophotometer against blank
after cooling to room temperature. DMSO (0.3mL) in the
place of compounds was used as the blank. For reference, the
various concentrations of ascorbic acid have been used.
3.1.4. Short-Term Study for In Vitro Antitumor Activity
[20]. Cells were collected, counted, and adjusted to 1 ×
106 cells/mL. The drug dilutions were made with phosphate
buﬀer saline, and the drug dilutions were further adjusted
to required concentrations. The drug dilutions were then
added to the Daltons Lymphoma Ascites (DLAs) cells and
incubated at 37◦C for 3 hours. At the end of 3 hours,
trypanbluedyeexclusiontestwasperformed,andpercentage
viability and percentage cytotoxicity were calculated.
4. Results and Discussion
For in vitro antioxidant activity, all the synthesized chalcone
and isoxazole-substituted 9-anilino acridines were screened
by DPPH assay, reducing power assay, and TAC almost all
the isoxazole-substituted derivatives have shown antioxidant
activity, among these compounds 5a, 5c, 5d, 5f, 5i, and 5j
having more potent antioxidant activity when compared
to standard ascorbic acid. The IC50 values, which is the
concentration of the sample required to increase 50% of
reducing capacity of the compounds, are shown in Table 1.
The synthesized ﬁnal compounds 5a–j were subjected
to short-term study for in vitro cytotoxic activity against
Daltons Lymphoma Ascites (DLA) cells. All the isoxazole
substituted derivatives were shown signiﬁcant cytotoxicity
andthecompound5ihasmo r epot e ntcyt ot o xicacti vity .The
results were shown in Table 2.
For the docking of ligands to protein active sites and
for estimating the binding aﬃnities of docked compounds,
an advanced molecular docking program, AutoDock Vina
version 4.0, was used in this study. The designed analogues
are docked towards the dsDNA octamer duplex in order to
ascertain their anticancer activity. The analogues show best
ﬁt Root Mean Square Diﬀerence (rmsd) value of 0.000.
5. Conclusion
A series of novel isoxazole-substituted 9-anilino acridine
derivatives have been synthesized. The synthesized com-
pounds have signiﬁcant antioxidant activity when compared
withstandardascorbicacidandalsoshowedsigniﬁcantcyto-
toxic activity by in vitro anticancer activity when compared
to the control. The molecular docking studies show a good
correlation between their biological activities screened and
autodock binding free energy. In particular compound 5i
shows signiﬁcant anticancer activity. Compound 5i have4 The Scientiﬁc World Journal
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Figure 1: Best aﬃnity mode of docked compounds.The Scientiﬁc World Journal 5
Table 1: Antioxidant activity of synthesized compounds 4a–j and 5a–j by DPPH method, reducing power assay and total antioxidant
capacity method.
S. No Cpd. Code IC50 values for DPPH
method (μg/mL)
IC50 values for reducing
power assay (μg/mL)
IC50 values for TAC
(μg/mL)
(1) 4a >1000 >500 >500
(2) 4b >1000 >500 >500
(3) 4c >1000 >500 >500
(4) 4d >1000 >500 >500
(5) 4e >1000 >500 >500
(6) 4f >1000 >500 >500
(7) 4g >1000 >500 >500
(8) 4h >1000 >500 >500
(9) 4i >1000 >500 >500
(10) 4j >1000 >500 >500
(11) 5a 18.30 ±0.4583 34.17 ±0.5783 89.60 ±0.7767
(12) 5b 50.23 ±1.048 68.27 ±0.5608 122.0 ±1.044
(13) 5c 17.53 ±0.088 22.13 ±0.5044 92.80 ±0.9074
(14) 5d 14.20 ±0.1528 26.43 ±0.5696 81.83 ±0.2404
(15) 5e 33.20 ±1.323 43.37 ±0.5925 111.8 ±0.8819
(16) 5f 12.67 ±0.1202 29.50 ±0.8718 91.43 ±0.2404
(17) 5g 27.00 ±0.8660 47.03 ±1.035 132.3 ±0.8090
(18) 5h 28.20 ±0.3464 37.30 ±0.4619 75.43 ±0.2404
(19) 5i 13.63 ±0.1764 19.23 ±0.4667 95.43 ±0.2404
(20) 5j 16.30 ±0.5568 20.53 ±1.004 65.97 ±0.5207
(21) Standard ascorbic acid 18.60 ±1.039 24.77 ±0.2404 86.17 ±0.5783
Table 2: Short term in vitro anti-tumor activity of synthesized compounds against Daltons Lymphoma Ascites (DLA) cells.
S. No Compound Concentration (μg/mL) % viability % cytotoxicity Cyto50 (μg/mL)
(1) 5a
1000 35.83 65.83
679.08 500 58.02 41.98
250 75.58 24.42
(2) 5b
1000 40.56 59.44
853.95 500 65.29 34.71
250 75.54 24.46
(3) 5c
1000 35.23 64.77
788.77 500 65.17 34.83
250 78.66 21.34
(4) 5d
1000 43.33 56.57
518.29 500 50.57 49.43
250 70.27 29.73
(5) 5e
1000 45.78 54.22
947.96 500 77.27 22.73
250 85.71 14.29
(6) 5f
1000 46.87 53.13
633.71 500 59.35 40.65
250 88.26 11.74
(7) 5g
1000 46.38 53.62
938.70 500 69.98 30.31
250 79.67 20.33
(8) 5h
1000 32.50 67.50
539.81 500 53.33 46.67
250 81.70 18.30
(9) 5i
1000 38.37 61.63
311.75 500 48.42 51.58
250 58.33 41.67
(10) 5j
1000 47.11 52.89
930.27 500 71.51 28.49
250 89.32 10.686 The Scientiﬁc World Journal
potent cytotoxic activity and is likely to be useful as drugs
after further reﬁnement. These derivatives will encourage
helping to design future anticancer agents with therapeutic
potentials.
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